← All trials
NCT03515369
Phase 4Interventional
Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use.
View on ClinicalTrials.gov ↗Timeline
- Start date
- May 31, 2018
- Primary completion
- Jan 31, 2022
- Completion date
- Jun 30, 2022
- First posted
- —
- Last posted
- —
- Enrollment
- 459
- Arms / groups
- 2 / —
- Source
- AACT · ingestion pipeline
Sponsors
- Eastern Hepatobiliary Surgery HospitalLead sponsor
- Fudan UniversityCollaborator
- Nanjing UniversityCollaborator
- Sun Yat-Sen UniversityCollaborator
- Second Military Medical UniversityCollaborator
- Eastern Hepatobiliary Surgery HospitalReponsible party - principal investigator
- Eastern Hepatobiliary Surgery HospitalStudy chair
- Fujian Mengchao Hepatobiliary HospitalCollaborator
- Xiamen Traditional Chinese Medicine Co., Ltd.Collaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.